Cartography raises $67M Series B, backed by Pfizer and Amgen

SFBN Feed: A year after collaborating with Gilead, Cartography maps out its own Phase 1 with $67M Series B https://lnkd.in/gGENCBDN Pfizer and Amgen’s corporate venture arms are jumping into T cell engagers by investing in Cartography Biosciences’ $67 million Series B. The Bay Area startup, which is developing bispecific and multispecific antibodies for cancer patients [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

A year after collaborating with Gilead, Cartography maps out its own Phase 1 with $67M Series B https://lnkd.in/gc2eQ8XF Pfizer and Amgen’s corporate venture arms are jumping into T cell engagers by investing in Cartography Biosciences’ $67 million Series B. The Bay Area startup, which is developing bispecific and multispecific antibodies for cancer patients [...]

Korean biotech VS PharmTech raises Series B bridge funding for global tech transfer of cancer radiosensitizer VS-101, showing complete response in Phase 1 trials. https://lnkd.in/gfh6yaV6

🚨 Breaking today: €308M lands in European biotech. One of the biggest raises of the year. German biotech Tubulis GmbH has closed a €308 million Series C, led by Venrock, to advance its antibody-drug conjugate (ADC) platform - one of Europe’s biggest biotech financings this year. It's a pretty important turning point... 🎯 Their Mission: Tubulis GmbH is part of a growing wave of biotechs transforming cancer therapy by: ➡️ Building ADCs that target tumours with extreme precision - sparing healthy tissue ➡️ Focusing first on ovarian and lung cancers, where options are limited and toxicity is high ➡️ Engineering platform-scale reliability - the leap from discovery to deliverability 💰 Why This Is Important: This round signals far more than capital inflow: → It shows global investors are backing deep science again, not short-term hype → It validates Europe’s emergence as a serious hub for complex biologics → It highlights a structural shift - oncology’s future will be engineered, not discovered For context: €308M is not common in Europe’s current market. It’s one of those pivot moments that shows where conviction - and capital - are heading next. 🌍 The Implications: 𝐅𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 → a future of more targeted, more tolerable treatment options 𝐅𝐨𝐫 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 → proof that precision manufacturing, not just discovery, will define the next decade 𝐅𝐨𝐫 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 → a clear signal that the next growth cycle is being built now, molecule by molecule €308 million..... 𝐂𝐨𝐧𝐯𝐢𝐜𝐭𝐢𝐨𝐧 𝐢𝐬 𝐛𝐚𝐜𝐤. #funding #biotech #ADC #investor #pharmaceuticals #growth

🗣️ Exciting news 🧬 We are pleased to announce a new research collaboration with Irimajiri Therapeutics, a Japanese leader in peptide mimetic chemistry. We will combine Irimajiri’s proprietary ACLS peptidomimetic library with the power of the Iktos AI- and robotics-driven drug discovery platform — in particular, MT-Bench™ cellular assays. ➡️ The goal: accelerate the discovery of novel inhibitors of protein–protein interactions (PPIs), a class of targets long considered challenging yet full of promise in oncology. This partnership reflects our shared commitment to push the boundaries of what is possible in drug discovery and to bring forward innovative treatment options for patients with cancers where unmet medical needs remain high. We look forward to the journey ahead with Irimajiri Therapeutics! 👉 Read the full story here:https://lnkd.in/eqy3V-nK #DrugDiscovery #AI #Oncology #Biotech #Partnership

SFBN Feed: Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round https://lnkd.in/gifSyjCe HAYWARD, Calif.–(BUSINESS WIRE)– #biotechnology–Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce an investment by Laurus Labs, India in Aarvik’s recently-concluded Series Seed 2 financing [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

🚀 Nanoligent takes off toward Phase Ia with a €12M funding round We are thrilled to share an extraordinary milestone for Nanoligent, one of the biotech startups in our portfolio, which has closed a €12 million funding round . Thanks to this investment, its lead drug, NNL1524, can move forward into Phase Ia clinical trials, bringing its innovative technology directly from the lab to patients. Nanoligent’s nanoparticles are not just advanced they are precise, intelligent, and targeted, capable of attacking tumors where traditional therapies fall short. This is a concrete example of how research can be transformed into real solutions that make a difference in people’s lives. 👏 We are proud to closely support this visionary and determined team, led by Montserrat Cano Biosca and Manuel Rodríguez, as they are reshaping the future of oncology therapies. Learn more about the news: https://lnkd.in/dcGcMvz4

"Immuto Scientific creates and leverages data that no other group in the world has.” - Spencer M. of DYDX Capital Excited for this $8M round... but also the partnership with Daiichi Sankyo US, to discover new drug targets in solid tumors using its proprietary structural surfaceomics platform and to develop antibodies against these targets. In this funding round, Tundra Angels is thrilled to join up with Spencer M. of DYDX Capital, Adam G. of Gravity Fund, and continue the journey with Greg Keenan, Joshua J. Carson, Katie Rice, and Mike Partsch at Wisconsin Alumni Research Foundation (WARF) Ventures, Great Oaks Venture Capital, Brad Bodden Wisconsin Investment Partners, among others. Collectively, we're excited to be part of unlocking the new era of data‑driven drug discovery. 🚀

𝗢𝘂𝗿 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗧𝘂𝗯𝘂𝗹𝗶𝘀 𝗿𝗮𝗶𝘀𝗲𝘀 𝗮𝗻 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗼𝗳 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 €𝟯𝟬𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 OCCIDENT participated in Tubulis GmbH's Series C round led by Venrock Healthcare Capital Partners with participation from existing and additional new investors including Wellington Management and Ascenta Capital. The funds will be used to accelerate clinical development of Tubulis' lead antibody drug candidates TUB-040, TUB-030, several preclinical programs and to expand its proprietary ADC platform technologies to bring ADCs into novel applications. Big congratulations to Dominik Schumacher, Jonas Helma-Smets, Ingo Lehrke, Günter Fingerle-Rowson, Bjoern Hock, Matthew Norkunas, M.D., Halley Gilbert and the whole team on this amazing success! We very much look forward to the next exciting steps in the company’s development. Read more: https://lnkd.in/d4yQnRZZ   #antibodydrugconjugates #ADC #cancer #tumor #lifesciences #biotech #healthcareinnovation

BridGene Biosciences, Inc., led by CEO and co-founder Ping C., Ph.D., has secured $28 million in Series B+ funding led by Bayland Capital 康君资本 , with participation from @GTJA Investment Group , Proxima Ventures , lapam confartigianato modena Capital, and Grains Valley Venture Capital. The San Jose–based biotech is advancing BGC-515, a covalent TEAD inhibitor for solid tumors, into Phase 2 clinical trials and expanding its proprietary IMTAC™ chemoproteomic platform across oncology and autoimmune diseases. Bayland Capital’s founding partner Yuexing Su highlighted BridGene’s differentiated platform as a breakthrough in targeting traditionally inaccessible proteins. The funding underlines growing investor confidence in platform-driven biotech innovations poised to reshape treatment paradigms. https://lnkd.in/gwywienm